C-RET

Cat. No.	Product name	CAS No.	Purity
T20742	TG-89	936091-56-4	98%
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cer...
T16995	TAS05567	1429038-15-2	98%
TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...
T10823	Trans-Pralsetinib	2097132-93-7	98%
trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET) extracted from patent US20170121312A1 (Compound Example 129).
T14928	Agerafenib hydrochloride	1227678-26-3	98%
Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM).
T12598	Pz-1	1800505-64-9	98%
Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.
T4301	AD80	1384071-99-1	98%
AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.
T1792	Regorafenib	755037-03-7	98%
Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).
T67779	Compound TPX-0046	2411115-73-4	98%
Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.
T62285	Enbezotinib	2359649-81-1	98%
Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.
T8222	Selpercatinib	2152628-33-4	98%
Selpercatinib is a tyrosine kinase inhibitor with antineoplastic properties(IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), r...
T8467	RET V804M-IN-1	2414909-94-5	98%
RET V804M-IN-1 is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).
T2586	Cabozantinib	849217-68-1	98%
Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 nM).
T6920	ON123300	1357470-29-1	98%
ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).
T2620	G-749	1457983-28-6	98%
G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
T2070	Agerafenib	1188910-76-0	98%
CEP-32496 is a highly potent inhibitor of BRAF.
T3065	TG101209	936091-14-4	98%
TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.
T9445	Vepafestinib	2129515-96-2	98%
Vepafestinib is a RET inhibitor with potential antineoplastic activity[1].
T2516	Amuvatinib	850879-09-3	98%
Amuvatinib is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
T0520	Lenvatinib	417716-92-8	98%
Lenvatinib is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.
T2094	Danusertib	827318-97-8	98%
Danusertib is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may ...

Cat. No.

Product name

CAS No.

Purity

Chemical Structure

T20742

TG-89

936091-56-4

98%

TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cer...

T16995

TAS05567

1429038-15-2

98%

TAS05567 is a potent, highly selective, and ATP-competitive Syk inhibitor (IC50: 0.37 nM). TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, ...

T10823

Trans-Pralsetinib

2097132-93-7

98%

trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET) extracted from patent US20170121312A1 (Compound Example 129).

T14928

Agerafenib hydrochloride

1227678-26-3

98%

Agerafenib hydrochloride is a highly potent inhibitor of BRAFV600E (Kd: 14 nM).

T12598

Pz-1

1800505-64-9

98%

Pz-1 is an inhibitor of VEGFR2 and RET (rearranged during transfection) tyrosine kinase that blocks the blood supply required for RET-stimulated growth.

T4301

AD80

1384071-99-1

98%

AD80, a multikinase inhibitor, inhibits RET, RAF, SRCand S6K, with greatly reduced mTOR activity.

T1792

Regorafenib

755037-03-7

98%

Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor (IC50s: 1.5/2.5/4.2/7/13/22 nM for RET/C-RAF/VEGFR2/c-Kit/VEGFR1/PDGFRβ).

T67779

Compound TPX-0046

2411115-73-4

98%

Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.

T62285

Enbezotinib

2359649-81-1

98%

Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.

T8222

Selpercatinib

2152628-33-4

98%

Selpercatinib is a tyrosine kinase inhibitor with antineoplastic properties(IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), r...

T8467

RET V804M-IN-1

2414909-94-5

98%

RET V804M-IN-1 is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).

T2586

Cabozantinib

849217-68-1

98%

Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 nM).

T6920

ON123300

1357470-29-1

98%

ON123300 is a potent and multi-targeted kinase inhibitor for CDK4/Ark5/PDGFRβ/FGFR1/RET/Fyn (IC50: 3.9/5/26/26/9.2/11 nM).

T2620

G-749

1457983-28-6

98%

G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.

T2070

Agerafenib

1188910-76-0

98%

CEP-32496 is a highly potent inhibitor of BRAF.

T3065

TG101209

936091-14-4

98%

TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.

T9445

Vepafestinib

2129515-96-2

98%

Vepafestinib is a RET inhibitor with potential antineoplastic activity[1].

T2516

Amuvatinib

850879-09-3

98%

Amuvatinib is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.

T0520

Lenvatinib

417716-92-8

98%

Lenvatinib is a Kinase Inhibitor. The mechanism of action of lenvatinib is as a Receptor Tyrosine Kinase Inhibitor.

T2094

Danusertib

827318-97-8

98%

Danusertib is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may ...